RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. EWTX | 0.00 |
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:
EWTX) with a Outperform and raises the price target from $48 to $59.